RNA Targets: Potential Therapeutics for Cancer and other Diseases

Target Name: RNU1-108P

NCBI ID: G106481957

RNU1-108P

Other Name(s): RNA, U1 small nuclear 108, pseudogene

RNA Targets: Potential Therapeutics for Cancer and other Diseases

RNA, U1 small nuclear 108, pseudogene (RNU1-108P) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is a small RNA molecule, with a length of approximately 200 nucleotides.

RNU1-108P is a transcribed gene that is located on chromosome 19 at position 108. It is a pseudogene, which means that it is a non-coding RNA molecule that has been generated from a coding gene. The coding gene for RNU1-108P is U1 small nuclear 108, which is a gene that has been identified as a potential drug target in the study of cancer.

The discovery of RNU1-108P as a potential drug target or biomarker is based on several lines of evidence. First, there is evidence that RNU1-108P is expressed in various tissues and organs, including the brain, heart, liver, and pancreas. This suggests that it may be a potential biomarker for these diseases. Second, there is evidence that RNU1-108P is involved in several cellular processes, including cell signaling, DNA replication, and repair. This suggests that it may be a potential drug target.

One of the potential benefits of targeting RNU1-108P as a drug target is that it has been shown to be involved in several diseases, including cancer. For example, studies have shown that high levels of RNU1-108P are associated with poor prognosis in several types of cancer, including breast, ovarian, and prostate cancers. Additionally, there is evidence that targeting RNU1-108P may be an effective way to treat certain types of cancer, such as breast cancer.

Another potential benefit of targeting RNU1-108P as a drug target is that it is a small molecule, which makes it relatively easy to manipulate and study. This allows researchers to test the effects of different drugs on RNU1-108P levels and to study its underlying mechanisms.

Targeting RNU1-108P as a drug target or biomarker is still in the early stages of research, and more studies are needed to fully understand its potential as a drug. However, the evidence that has been gathered so far suggests that RNU1-108P may be a promising drug target or biomarker for a variety of diseases. Further research is needed to confirm these findings and to develop more effective treatments for these conditions.

Protein Name: RNA, U1 Small Nuclear 108, Pseudogene

The "RNU1-108P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU1-108P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets